NVAC | June 13, 2024 | Day 1, Part 3

USDOHAHS
156 followers
1 Video View·Jun 25, 2024
The National Vaccine Advisory Committee (NVAC) recommends ways to achieve optimal prevention of human infectious diseases through immunization. You can learn more about this advisory committee by visiting the NVAC website at hhs.gov/vaccines/nvac/index.html.
--
U.S. Department of Health and Human Services (HHS) | http://www.hhs.gov | HHS Privacy Policy | http://www.hhs.gov/Privacy.html
>> Robert Hopkins: All right. Welcome back from our break. Our next panel is
Breast Cancer Vaccine Innovations in the Works. And we have three presenters for this panel:
Dr. Nora Disis, the Director of the University of Washington's Institute of Translational
Health Science and the Center for Translational Medicine and Women's
Health at the University of Washington, among other roles; Dr. Kiran Dhillon,
the Executive Director of the Cancer Vaccine Institute, the University of Washington;
and Kristen Dahlgren, who's the Founder and CEO of the Cancer Vaccine Coalition.
Dr. Disis, I see you on video. Your slides are up. You have the floor.
>> Nora Disis: Thank you very much. May I ask,
is someone else forwarding the slides or can I share the screen?
>> Robert Hopkins: We will advance your slides for you. Just say "next slide" for us.
>> Nora Disis: Thanks very much. Thank you so much for the opportunity to talk
today. My name is Nora Disis, and one of my other
roles is Director of the UW Medicine Cancer Vaccine Institute. Next slide.
We're at a tipping point for cancer vaccines, and we're at this tipping point for four major
reasons. First, we know the type of immune response we need to have an anti-cancer effect,
and that is a type one T-cell response with cytotoxic T-cells and cytokine-releasing CD4
T-cells that can actually kill tumor cells. The second tipping point is that hundreds of tumor
antigens have been identified, and this is really allowing us to create precision vaccines either
targeted to specific tumor types or targeted to the specific patient. The third tipping point is
that we have safe and immunologically effective vaccine delivery technologies now, and these are
new nucleic acid-based technologies, mRNA and DNA, and they allow the application of multi-antigen
vaccines, you know, because cancer isn't caused by one protein. And finally, cancer vaccines are
being tested in appropriate patient populations really across the cancer spectrum from prevention
all the way to treatment, being integrated into combination immunotherapy approaches. Next slide.
It seems like you can't open a newspaper these days without reading about a successful cancer
vaccine trial that's showing promise. And this really is coming on the tail end of
a decade of explosion in cancer vaccine research. And this slide really shows that
explosion. On the left-hand side of the slide, you can see over the last decade,
the number of publications on cancer vaccines really is taking off. And the
United States is leading this explosion with 50 percent of these publications
really coming from our country. The impact of these publications is tremendous. Next slide.
In fact, other countries are taking action based on the impact that our country's research is
having on the vaccine field. And in fact, in the last several months, the United Kingdom
has started a major cancer vaccine initiative where their plan is to enroll 10,000 cancer
patients across a variety of different cancer tumor types and to immunize 10,000
patients with mRNA personalized vaccines for the treatment of their existing cancer. Next slide.
Most patients with cancer do have immune responses to their tumors,
and those immune responses are to two major categories of proteins. The first category of
proteins that are immunogenic in cancer are foreign proteins, and those really comprise
viruses such as HPV in cervical cancer or mutations, which really occur in a
certain select group of cancers such as melanoma, kidney cancer, non-small cell lung cancer. Now,
when these immunogens are recognized by the immune system, they give a very strong killer
type of an immune response, a type one immune response with cytotoxic T-cells and really
a type one immune microenvironment. Although these occur in the minority of cancer patients,
this inherent endogenous immune response allows immune checkpoint inhibitors,
which operate just by unleashing this endogenous immune response as a form of cancer therapy.
But the vast majority of cancer patients respond to another category, the other category of
immunogenic protein, which are non-mutated, aberrantly expressed proteins. These are more
similar to self -- they give a self-signal, and the immune responses that are generated in these
patients actually is a regulatory immune response that dampens that type one immune response. So
when you're constructing a cancer vaccine, the adjuvant, the delivery, really will be dependent
on the antigen type, because this either will allow you to augment pre-existing type
one immune response or have an antigen delivery system and management type that will allow you
to kind of change that regulatory response into a type one immune response. Next slide, please.
Now, whether a vaccine is composed of a non-mutated antigen or a mutated or viral antigen,
more and more vaccines are being encoded into nucleic acid approaches, either mRNA or DNA. Now,
the major reason for these is that these approaches have been around for a long time,
and they've been shown to be safe and effective. But there are numerous other reasons. These
approaches are adaptable to multiple antigens, which is going to be the way that we overcome
cancer. These approaches are superior in the generation of cytotoxic T-cells in that type
one immune response. The vaccines themselves are very stable over time and at higher temperatures,
so they're easy to travel around. DNA vaccines, in particular, persist at the injection site
for a short period of time after immunization, so they auto-boost the patient. They're low cost, and
they're rapidly manufactured, and this is really ideal for personalized mRNA vaccines. Next slide.
So what I'd like to do now is just give you a couple of examples of these more modern
cancer vaccine approaches. And I'm going to start with talking about mutation-based
personalized vaccines. Now, many cancers are associated with a lot of mutations,
as I mentioned before, and there are different types of mutations. You can have translocations,
you can have somatic mutations. These all create unique proteins in the tumor
that haven't been recognized by the immune system before.
And so basically, to create a mutation-based personalized vaccine,
we have to have the patient's cancer. The cancer undergoes
sequencing, as you can see on the right-hand side of the slide. The tumor-specific sequences
are then analyzed through artificial intelligence to identify mutations that have a high likelihood
of interacting with the patient's own MHC or immune system. And then from there,
there's an in vitro validation to see if those predicted epitopes actually do
interact with the patient's immune system. And then these epitopes are rapidly constructed into
a personalized vaccine that may consist of 10, 15, 20 different mutations. So you can see rapid
vaccine manufacture is critically important for mutation-based personalized vaccines. Next slide.
This is a recent publication of a personalized vaccine for pancreatic cancer. The way the vaccine
was made was just as I told you before, taking the patient's tumor at the time of diagnosis.
The patients had surgery, so their pancreatic cancer was resectable. The vaccine was made
based on the mutations that were present in the patient's tumor. The patients were vaccinated
after they were treated with Atezolizumab, which is an immune checkpoint inhibitor that helps
unleash the vaccinated immune response. Then after vaccination, the patients got standard therapy,
which was adjuvant chemotherapy, and then after the chemotherapy,
they had booster immunizations. You can see this regimen on the left-hand side of the slide.
On the right-hand side of the slide is the clinical outcome. Although it was a small study,
the clinical outcome was striking. 50 percent of the patients were able to develop immune responses
against the mutations in their tumors. This can be seen by the yellow bars. And 50 percent of
the patients did not. But those that did immunologically respond to their mutations,
compared to those that did not respond, had superior clinical outcomes. Both the
relapse-free survival and the overall survival of those patients has not been reached at this
time. And this vaccine is now going on to a large randomized phase two study. Next slide.
Now, artificial intelligence has really advanced the engineering of vaccines targeting non-mutated
antigens. What we've found is that within the natural sequence of these non-mutated antigens
are epitopes that predominantly elicit those regulatory responses and epitopes
that selectively elicit type one immune responses. So with this, you can identify
proteins that are cancer drivers for particular tumor types. Similar to mutated antigen vaccines,
use epitope editing to find those segments that have the right type of immune response,
type one selective responses, and basically create a multi-antigen
epitope-based vaccine very similar to mutated antigen vaccines. Next slide.
This is an example of a vaccine designed to prevent breast cancer recurrence,
targeting a single antigen, the HER2/neu protein, which is overexpressed in about 30 percent of
breast cancers. But this antigen is unique as it's a very dominant driver oncogene of this
particular subtype of protein. A vaccine encoding TH1 selective epitopes using the technology that
I just told you about could be formulated and went into a very large phase one clinical trial
in very advanced stage HER2/neu-positive breast cancer patients, 66 of them. This
was a dose escalation study. The patients had no evidence of disease or bone-only disease,
and the outcomes were to look at the safety and clinical response. Next slide, please.
The vaccine was very immunogenic. In fact, all doses elicited an immune response.
And at the time of when this was reported last year, 50 percent of patients with stage three
and stage four disease had not had a relapse. And in fact, none of the stage three patients had a
relapse with a follow-up of over eight years. Seventy-five to 85 percent of the patients
are still alive. And you would expect the median survival to be about 58 months. And in this trial
still at 10 years, the median survival has not been reached. The vaccine is now in phase two
randomized studies in breast and gastric cancer and a basket cancer for different
types of HER2/neu-positive cancers such as uterine, lung, and other cancers. Next slide.
So, this is just a few examples of where cancer vaccines have come quite far in the
last decade. Numerous cancer vaccines are moving forward in multiple clinical scenarios. In fact,
on clinicaltrials.gov, cancer vaccines are probably one of the most rapidly growing
clinical trials that are being today. I've shown you vaccines to treat or prevent cancer
recurrence. There are vaccine clinical trials right now to intercept cancer by
treating pre-invasive lesions and even to prevent cancer in patients that are genetically high risk.
At the Cancer Vaccine Institute at the University of Washington,
we have campaigns going on in lung, breast, colon, prostate, ovary, and bladder cancer.
These are the cancers that cause 50 percent of cancer deaths and diagnoses in the United
States. And we're working on cancers that are moving through -- vaccines that are
moving through all these clinical scenarios to prevent, intercept, and treat cancers.
And with that, I'd like to turn this over to Dr. Kiran Dhillon.
>> Robert Hopkins: Thank you very much. Dr. Dhillon, you have the floor.
>> Kiran Dhillon: Okay. Thank you very much to the committee for giving us the opportunity to
share this work. And as you've heard from Dr. Disis, cancer vaccines are here and
moving their way through clinical trials. So, what I want to focus on for my portion of this
presentation is actually specifically talking about clinical applications of these vaccines,
which Dr. Disis alluded to. So this includes the prevention of cancer recurrence, treating cancer,
and then finally preventing or intercepting cancer. While we're making progress across
the front, across all of these different areas, the vast majority of our early work has been in
the prevention of cancer recurrence. I'm going to give you examples of work that's
happening in each of these spaces that illustrate the progress that's been made.
So, you just heard about an exciting phase one study for HER2-positive breast cancer. And this
was published in 2022, but the rationale behind our approach to treating cancer -- preventing
cancer recurrence was if we can target cancers at the time where the disease burden is lowest,
so giving patients a vaccine once they've had a complete treatment and have no evidence
of disease or bone-only disease, it gives the immune system the chance to develop that immune
response to recognize and eliminate any cells that might be remaining and subsequently grow. So,
in addition to the breast cancer study, we've also published a study in advanced
ovarian cancer with a vaccine that targets a protein called IGF-BP2 that's expressed
at very high levels in ovarian cancer. I'm going to talk about the specifics
of that study in a little bit when we talk about preventing ovarian cancer.
And ongoing, we have two phase one clinical trials
and two phase two clinical trials in breast cancer. Now we're moving from
preventing recurrence in advanced-stage disease more to earlier-stage disease,
stage one to stage three breast cancer. So, when we talk about the treatment of breast
cancer and having vaccines supplement that -- a really interesting example is one of a
vaccine that we call STEMVAC. STEMVAC targets a specific population of cancer cells called
cancer stem cells. This is a small population that actually drives resistance to therapy,
drives metastases, and drives a recurrence that may happen subsequent to treatment.
So, we identified five proteins that are expressed at high levels in cancers and are found to be
associated with cancer stem cells. We formulated a five-antigen DNA vaccine called STEMVAC. When
we tested this in a mouse model for breast cancer, we found that with the vaccine alone,
we could prevent cancer in about 50 percent of mice. So, this vaccine was taken to a phase one
clinical trial. Again, this is a dose-escalation study that was done in advanced stage, so stage
three and stage four breast cancer. These patients had either triple-negative breast cancer or had
hormone receptor-positive cancer. Patients received three vaccinations one month apart,
followed by two boosters at three and nine months. These patients are in long-term follow-up, but for
immune responses, we found that we could detect immune responses to all five of the antigens that
were part of the vaccine. And boosters were indeed actually really important. They significantly
boosted the level of response in these patients, and the levels of responses were quite high.
So, cancer stem cells aren't just found in breast cancer; they're actually found in many different
kinds of cancers, as you can see on the left here, including lung and others noted here. So,
we think that this vaccine is actually going to be effective, not just for breast cancer,
but for treating cancers that tend to have some stem cell-like properties,
which we can detect using various methods. In fact, we have a phase two clinical trial with this
vaccine ongoing in non-small-cell lung cancer, in addition to a phase two in non-metastatic
triple-negative breast cancer. We think that STEMVAC may actually also be really effective at
specifically targeting metastases. It's slowing or maybe stopping the growth of metastatic lesions.
And we're currently developing two different trials, both for breast cancer. In one case
for metastatic triple-negative breast cancer and in another for hormone receptor-positive
cancer. The first one, the triple-negative breast cancer, we hope to open in early 2025.
Now moving from treatment to prevention, right? This is, sort of, where we all want to be,
preventing cancer before it becomes invasive. What you see here is the evolution from normal
tissue to invasive cancer all the way on the right. As you can see, note that there are
several precancerous states that can be identified in many kinds of cancers. So,
what if we could develop vaccines that would actually target these precancerous lesions,
preventing those lesions from becoming invasive cancer? This is, in fact, what we're trying to
do across many different kinds of cancers. I've listed here some of the precancerous
lesions that are associated with various cancers: prostate intraepithelial neoplasia,
prostate cancer, adenomatous polyps. These are identified during colonoscopy screenings
and such for preventing colon cancer. Ductal carcinoma in situ is a precancerous lesion
often identified in breast imaging that can lead to breast cancer, and it's often treated
very much like breast cancer. We think that vaccines will play a significant role there.
And then for ovarian cancer, there's a lesion called serous tubal intraepithelial carcinoma.
It's a mouthful, we'll call it STIC for short. This is thought to start in the Fallopian tubes,
and these STIC cells migrate out to the ovary or to the peritoneum to seed cancers there. Ovarian
cancer is an important one to consider because it's known as a silent killer.
It generally is not diagnosed at earlier stages. Usually, patients are diagnosed at
stage three or stage four. And folks who have a family history of ovarian and breast cancer,
those who have known genetic mutations, tend to have a higher incidence of STIC
that's identified. So, these people can undergo preventative surgeries to remove fallopian tubes
and ovaries. That reduces the risk by 80 percent but doesn't completely eliminate it. The thought
is that the cells have already migrated out of the fallopian tube to seed the cancer elsewhere.
STIC can also be found incidentally in people who have surgery for total hysterectomy in a subset
of the population. So, that population could also benefit from a vaccine. So, of course,
can we develop a vaccine that specifically targets STIC? And we have evidence from
the ovarian cancer study that I mentioned earlier that we think we can do this. So,
this is the IGF-BP2 vaccine that we tested in advanced-stage ovarian cancer patients.
IGF-BP2 is not only an ovarian cancer antigen, but it's also associated with STIC as well. So,
we were able to achieve immune responses in patients who were vaccinated. We followed
these patients for eight years and found that a third of these patients didn't recur. And when
we look at overall survival, almost half of these patients are alive eight years after vaccination.
For comparison, the median survival for this population is only 18 months. So,
quite remarkable and something that we're quite excited about. We're now
developing a vaccine for STIC that not only includes epitopes from IGF-BP2,
but we're identifying and testing additional antigens to create a multi-antigen vaccine
that will first be tested in mice and then hopefully human clinical trials.
So, as another example of a disease, this is, you know, one caused by HPV infection. Vulvar
intraepithelial neoplasia is a precancerous lesion that can develop into invasive disease. This study
was published by Kentur et al. in 2009 in the New England Journal. In this case, they vaccinated
people who had stage three VIN, this precancerous lesion, with a synthetic peptide for the E6 and
E7 proteins of HPV. They looked at three, 12, and 24 months to look for clinical response and immune
response in these individuals. And what they found was that at 12 months, 79 percent of these
individuals had some sort of clinical response, either partial or complete. Forty-seven percent
of those had a complete response, and that was maintained into 24 months. They also saw that
all the folks who were vaccinated actually had an immune response, and you could correlate the level
of immune response to the actual clinical response as well. So quite encouraging.
So, the final example I give you for cancer prevention for a vaccine is a
case of where we're trying to target a cancer risk factor, in this case,
obesity. So, obesity is associated with many kinds of cancers: breast cancer, colon cancer,
endometrial, others. And of course is associated with all kinds of other disease states, including
metabolic syndromes, diabetes, hypertension. The cause of all of these is thought to be
inflammation that comes from fat tissue, so inflammatory fat, that can cause the metabolic
dysregulation within the fat tissue and also in the immune environment as well. And losing weight
does not reduce that problem. The immunologic memory stays even after weight loss has happened.
So, you know, so far, we've talked about vaccines. Dr. Disis talked about these type
one inflammatory vaccines. In this case, what we would have to do is actually reduce inflammation,
right? So, using the same technology that we talked about, we use the other side of
it to develop an anti-inflammatory vaccine by selecting epitopes that would elicit a type
two anti-inflammatory response. And so that's what we did. We found multiple epitopes that are
associated with inflammatory fat, and we developed a vaccine called adipocyte-directed vaccine,
or ADVAC. We have very clever names for vaccines [laughs], and we vaccinated mice that we feed a
Western diet, so high sugar, high fat diet. These mice become obese, and they start to display some
of the characteristics we see in humans in similar states, meaning metabolic syndrome, so they become
diabetic. And this particular model is also prone to developing breast cancer at high incidence.
What you see on the right is when we vaccinate these mice with ADVAC, we can actually correct
that diabetes in these mice. This is the glucose tolerance test, but we've also done insulin
tolerance tests, and we can prevent breast cancer in about more than half of these mice as well. So,
currently, this vaccine is being investigated very thoroughly to look at impacts on other organ
systems and to do extensive safety studies, and we hope to take it to IND in the next few years
for clinical trials. In addition to cancer and diabetes, another application of this
might be non-alcoholic fatty liver disease as well. So, a lot of work is ongoing right now.
So, with everything that Dr. Disis has shared and I shared, I hope that, you know, we can all in
this room envision a future that's cancer-free and a large part to what vaccines can do. And,
you know, we think about this as vaccines that can really help ameliorate risk for
people at different levels of cancer risk. For example, folks who are at intermediate
risk due to chronic inflammation. We talked about obesity, but inflammatory bowel disease is another
scenario that you could possibly imagine this working in. Those folks can benefit
from a vaccine to target that risk factor and to prevent cancer in those individuals.
Folks who are at higher risk, so these are folks who might have a genetic mutation or have a strong
family history or have had a precancerous lesion identified on a cancer screening, could benefit
from some of the vaccines that I shared with you today to intercept that cancer at an early
stage or to prevent it. And then those at very high risk who have already had cancer diagnosed
and are at high risk either for recurrence or from the cancer itself that's ongoing,
I hope you've seen that, you know, we have vaccines that are currently in the works
to be able to treat those cancers and also prevent their recurrence.
So, all of this work is done at the cancer -- most of the work I talked
about is done at the Cancer Vaccine Institute. We're located in Seattle,
and this is our team. And to be able to do everything that I've talked about,
we have a very interdisciplinary team that actually has specialized cores, and
under one roof we're able to do discovery work, translational work, and clinical trials. And
I invite you to check out our website, UWCVI, for more information. And I've added Dr. Disis
and my emails up there, so please feel free to reach out with any questions. Thank you.
>> Robert Hopkins: Thank you very much, Dr. Dhillon. Our final presenter in this
panel is Kristen Dahlgren from the Cancer Vaccine Coalition.
>> Kristen Dahlgren: Hi there. Thank you so much for having me. I want everyone to just
absorb some of those results for a minute because those are the results and that's the conversation
that I had with Dr. Disis back in September that made me leave my job as an NBC correspondent to
found the Cancer Vaccine Coalition, formerly known as Pink Eraser Project. I've heard this
described as the most hopeful time in history for cancer research, and that came from a long-time
scientist. We are actually hearing people use the word cure associated with cancer,
use prevention associated with cancer. Those are things that we couldn't have imagined just
a few years ago. So, we all probably have someone who's been impacted by cancer. So
just think about that cancer-free future where we don't have to have those toxic treatments,
the amputations of a part of our body, where the bulk of the work could actually be done by
these vaccines. And that's what we're trying to build at the Cancer Vaccine Coalition.
So, this is me. I'm an award-winning, blah, blah, blah, correspondent with NBC News,
including the Today Show and Nightly News for more than two decades. I was going about my
life. I probably spoke with some of you about measles outbreaks or infectious diseases or
flu every year. Those were the stories that I was covering. And then in 2019, I was diagnosed with
stage two invasive ductal carcinoma. I did eight rounds of ACT chemo, had a double mastectomy,
did 25 rounds of radiation. Since then, I've had six surgeries including LVA, DIEP flap, a revision
of the DIEP flap, flap removal, implants, and more revisions. Today, some of my symptoms: I have no
feeling in my chest, abdomen, part of my lower leg. I have limited shoulder mobility. I have lung
fibrosis from the radiation. I'm in chemically induced menopause, that I have to travel for
hours every 10 weeks to Memorial Sloan Kettering and then four hours back home because I get a
shot that isn't covered by my insurance to get it anywhere other than at Memorial Sloan Kettering,
where I started treatment and where somehow they're able to get things like that through.
Someone at the NIH at a meeting recently asked me, we have great treatments for breast cancer. Why
do we need a vaccine? Well, I give you those examples as to why we need a vaccine. Treatment
can be devastating. We're called survivors and warriors, but the reality is I will never again
feel like my body is my own. I'm constantly aware of what it went through. And I'm not
complaining. I'm grateful to be alive. But you won't hear anyone that's a survivor complaining.
And the reality is, I would argue, that breast cancer has been normalized in spite of some of
these facts. So every two minutes, someone in the U.S. is diagnosed with breast cancer. One in 40
is a woman's chance of dying from breast cancer here in the U.S. in spite of these
great treatments. You've probably heard this one-in-eight figure. That's how many women in
the U.S. have a chance of developing breast cancer in her lifetime. And one in three is
how many new female cancers in the U.S. will be from breast cancer every year. So, yes,
we do see life-extending, life-saving treatments for some cancers. But I think we can do better.
I was at the Milken Conference recently, and I heard a powerful question asked by the founder
and chairman of Moderna. He said, why did we put more weight on the lives lost during COVID
than we are now? And I think that question is that we saw such amazing collaboration. We saw
the pipeline being streamlined. We saw the FDA working to lay out the endpoints to work with
the scientists who were developing COVID vaccines. And so, his question is really,
can we do that again? And why aren't we doing that again? So, in September of 2023, I met Dr. Disis,
and we were also asking that question. You heard her describe a tipping point
for cancer vaccines. So, can we accelerate the process? Can we see a COVID-style push to move
scientists out of their silos, to engage the public, to involve industry, to streamline the
pipeline? And I put this in capitals for all of you, to bring in the government.
We have already moved scientists out of their silos. This is our team. So, we have
Dr. Disis from the University of Washington, Dr. Larry Norton from Memorial Sloan Kettering,
Beth Mittendorf from Dana Farber, Dr. Powel Brown from MD Anderson, and Dr. Tom Budd
from the Cleveland Clinic among those who are working with us. Can we engage the public? Well,
that's where a journalist comes in. So, when I announced that I was leaving the Today Show,
we did get a lot of coverage. We are working on engaging the public every day on spreading
the word about cancer vaccines. Yesterday, I just forwarded something about a glioblastoma
vaccine that's in development. So, we're seeing so much in this space.
I would give us a half-check maybe for involving industry, but I've also been
traveling to medical conferences and the Milken Conference, and these are some of the companies
that I've been in touch with, some of them who are developing cancer vaccines. Then we
get to streamline the pipeline and engage in government. That is a work in progress. So,
some of the things we hope to do: we want to accelerate established concepts. We want to
quickly enroll studies and design clinical trials to yield swift go/no-go decisions
for advancement. And then we'd like to work with the FDA to provide a roadmap
à la COVID. We've seen that this can work, and I think together we can do this again.
How do I know? Because they're doing it in another country. And while Nora said we are
ahead of everything here in the U.S., I want to offer up the U.K., which she also alluded to as
an example. So, they call it the U.K. Cancer Vaccine Launchpad. This is a picture of Dr.
Lennard Lee of Oxford, who I've been talking with quite frequently. I'm using some of his slides
with his permission and as an example of what can be done. He also invited me to their Great
Britain Cancer Vaccine Summit, the first one. They had about 350 people there from all different
hospitals and all different cancers working on this. So, according to them, a global vaccine
technology race is underway. This is sort of where we are. Hundreds of vaccines are in phase one,
about 50 cancer vaccines are in phase two, and just a few are in phase three studies.
They've framed this as a race. The U.K. is winning. I don't know if anyone here
is competitive, but they really are saying that they are going to be the first ones to see these
widespread cancer vaccine trials. And I would say that we here in America can do something as
well. The National Cancer Vaccine Advance, this is what -- when they launched it. So, as Nora said,
it's this plan to get 10,000 cancer vaccines. This is how it works. So, keeping in mind that
pharma partners are actually paying and providing the vaccines. So, what their government is doing
is providing these 16 active cancer vaccine sites, and they're helping to refer and enroll patients.
So, 500 patients or more have already consented to these trials in year one. We also have a huge
pool of people who really want these vaccines. I talked to organizations like Touch, the Black
Breast Cancer Foundation. They have 3,500 women signed up, waiting for breast cancer vaccine
trials. We just need to get them to them, make sure they're accessible, and get them enrolled.
In the U.K., these are the cancers that they're currently working on: lung, head and neck,
bowel, pancreas, prostate, and melanoma. You'll note that breast cancer isn't yet
up there. We already do see some vaccine treatments in bladder cancer. And they're
using mostly personalized vaccines, with which Dr. Disis went over. Cancer vaccine,
thank you. Cancer Vaccine Coalition is vaccine type agnostic, so we want to work with anyone
who's developing a cancer vaccine, whether it's personalized or off the shelf, like the ones being
developed at the University of Washington. This is just some of the coverage that they've seen,
so they really are seeing this widespread public sentiment, public education about
the different types of vaccines and the patients that are involved in them. These are just a few
of their goals: initiating a global advance of vaccines for cancer and immunity against cancer,
transformative benefit achieved across multiple cancer subtypes for early and late-stage cancers,
and then to place those 10,000 people through clinical trials by 2030.
So, I'm sure you've all noticed we do not have an NHS. So, how does it translate to here in the
US? So, well, we're ahead of the world or in step on COVID-19 vaccine development. I would
say that we have American ingenuity. We do have national pride. We have philanthropy. We have
strong industry with a history of success in these types of collaborations from the Space Race to
the Manhattan Project. And we also have a shared hatred of cancer, which isn't nothing. Wouldn't
it be nice if we all came together and we saw the country get behind this type of national effort,
rallying around something -- especially something with the word vaccine in it? I will say I was
a little concerned when we first formed that there would be pushback on using vaccine. And
I was worried people wouldn't understand that, in the beginning, these cancer vaccines would
be treatment or therapeutic vaccines. I will say that I haven't seen that type of pushback at all.
I've only seen two messages on social media, and the worst they said was great, another vaccine.
Well, as I pointed out, this is never going to be something that's vaccine -- vaccines
are not going to be mandated, cancer vaccines are not going to be mandated
by the government. It could be part of your treatment or not. You also don't have to do
chemotherapy if that's recommended by your doctor. We have people on both
sides of the aisle helping us with this effort. And so, it's really encouraging.
So, what is Cancer Vaccine Coalition? ICS is the hub. So, we can bring all these pieces together:
the researchers, industry, trial participants, government. We're raising money to help fund
these trials. And we're also working with different organizations. I know that the
National Breast Cancer Coalition is here as well. And we'd like to bring in all of these groups,
all of the stakeholders together to get this moving. CVC brings, creates an ecosystem.
Bringing together these stakeholders, connecting the researchers to collaborate on the ideas,
inspiring each other and innovating. They talk at least once a month together. We're
planning a cancer vaccine summit in San Francisco on November 4th, we invite you
all. We're also talking, as I said, to industry partners, connecting government stakeholders,
philanthropic donors and investors, and connecting patients to enroll those trials quickly.
So, our mission is to speed the development of vaccines and end breast cancer as a fatal disease
with other vaccines to follow. And we're aiming to revolutionize cancer research by being that hub.
So, instead of what Dr. Dhillon and Dr. Disis say could be a long road ahead, vaccines are coming,
but in the current system, we may not see them until 2050. Or, if we all come together,
it's really possible to see vaccines to market by 2030. I did the math. That's 860,000 lives lost to
breast cancer in that time. So, we could be saving those people. And then think about the impact in
places like Sub-Saharan Africa, where there's no diagnosis, there's no treatment options. If
we were to get these off-the-shelf vaccines, it really could be revolutionizing those places and
those women's lives. The reality is we spend $26 billion or more on breast cancer care
alone annually. I've heard from these scientists that for less than $2 billion, and I padded that
number, we could have safe, effective breast cancer vaccines to market. So, why wouldn't
we invest in it now? Think about the return on investment and end to cancer as a fatal disease.
Success in breast cancer vaccines also equals success in other solid tumor cancer vaccines.
I will leave you with the reason that I'm doing this, a picture of me with my eight-year-old.
I want her to have her mom around for years to come. I want her to grow up in
a world where she's not seeing her friends getting this disease at an increasing rate,
where she doesn't have to either make terrible choices about preventing the disease or live
with it and have to go through things like these toxic treatments. I think we can build a better
world for the next generation and I invite you all to join me.
>> Robert Hopkins: So, I want to thank all three of you, the members of our panel,
and Cole. Are there any questions or comments from members of the committee,
either here in the room or online? I'm going to take the chair's prerogative and throw out
my first question to begin with. One of our real challenges in infectious disease
prevention vaccines is immunosenescence. We can have drop-offs in immune responses to
vaccines at different ages, depending on the particular vaccine or the particular target.
Have you seen any evidence that that's a challenge with cancer vaccines as well?
>> Nora Disis: If I could answer this, this is critically important. In fact,
that pancreatic cancer study has gone on to demonstrate that the longevity and persistence
of the immune response is associated with those clinical outcomes. Clearly, there will have to
be booster immunizations, but in our studies at the Cancer Vaccine Institute, we've seen
persistence of memory responses at fairly high levels years after the end of vaccination. Now,
in patients with cancer, this might be because they have immunogen and their bodies continuing
to stimulate that immune response. And I know those clinical trials that are being performed
in patients at earlier stage disease, we have one looking at patients with stage one and
stage two cancers that may not have a reservoir of antigen. Looking to see how long immunity persists
is going to be critical, but clearly booster vaccinations will be needed in the long term.
>> Robert Hopkins: Thank you. Other questions or comments? Well, I think you've stumped us.
Fascinating presentations. We want to thank all of you, both for your work. We look forward to seeing
more going forward, and Kristen, we like the vision for the future. All right. We have reached
our time for the day for public comment. And I understand we have some public comments, both --
>> Ann Aikin: I think we just have one [inaudible].
>> Robert Hopkins: One? Okay, we have a potential public comment in the room.
Give our speaker a chance to come to the microphone.
>> Michelle Tregear: All right, thank you. Well, first of all, I want to just say that was an
excellent panel. I have a very strong interest in vaccines, cancer vaccines, and prevention
vaccines. So, good afternoon. My name is Michelle Tregear. I'm a 15-year breast cancer survivor,
and I serve as the Chief Programs Officer for the National Breast
Cancer Coalition. And I'm here just to present a little bit about NBCC
perspective and also our work in the breast cancer vaccine space.
So, founded in 1991, NBCC is a collaboration of activists, survivors, researchers, grassroots and
national organizations that we've come together to end breast cancer through the power of action and
advocacy. NBCC's major research arm is its Artemis Project, which is an advocate-led, mission-driven
model designed to develop strategic and innovative plans to save lives by focusing on primary
prevention and the prevention of metastases. Now, when we launched the Artemis Project in 2010,
the first question we sought to tackle was, can we develop a breast cancer prevention vaccine? We
convened researchers, breast cancer advocates around this bold idea and have since sought
to develop a safe, cost-effective prevention vaccine that targets all three major subtypes
of breast cancer in order to reduce both the incidence and prevent death from breast cancer.
Now, the NBCC and Artemis Project awarded initial seed grants back in 2011 to investigate potential
viral causes of breast cancer as well as to identify antigen targets for candidate vaccine
and then also to begin the preclinical work. Over the past 10 years, the Artemis Projects,
in collaboration with Dr. Keith Knutson at the Mayo Clinic, have developed a vaccine construct
as well as the phase one safety trial protocol. And in 2020, the Artemis vaccine research
plan was accepted by the NCI's PREVENT program, which aims to bring promising cancer prevention
interventions through preclinical development. With their support, we are currently in the
process of manufacturing the vaccine and anticipate a 2025 phase one trial launch.
So, as our vaccine, as well as these other vaccines, progress through development,
clinical trials, and ultimately go to market, we must remember that they must be
clinically effective, broadly accessible, and affordable to achieve their goals. Too often,
treatments developed via the traditional industry model failed to meet this critical
need. That is why NBCC is currently investigating traditional as well as non-traditional drug
development strategies to ensure the broadest possible accessibility and affordability.
NBCC recommends to this committee that this program establish, if it so chooses to pursue
cancer vaccines, a plan to obtain consensus regarding the long-term outcomes that should form
the basis of approval of breast cancer prevention vaccine or any cancer prevention vaccine. We also
recommend that the program establish a strategic plan to engage broad stakeholder involvement,
including patient advocacy organizations, to ensure global access to all cancer vaccines
under development that ultimately prove to be efficacious. To achieve optimal public health
outcomes, the committee must prioritize making proven interventions accessible and affordable to
those in need regardless of their demographics, geography, or socioeconomic status. Thank you.
>> Robert Hopkins: Thank you for your comment. Just to let the members of the
committee know that there's also written comments from this organization that have
been sent to each of you. Are there any comments online? Give us just a moment.
>> Ann Aikin: [inaudible] Colton, okay, hold on.
>> Robert Hopkins:
All right. We do not have any verbal comments online. As such,
we will adjourn our first day of the June 2024 NVAC meeting. I would like to
encourage you to join us tomorrow morning for day two of our meeting starting at --
>> Ann Aikin: 9:00 a.m.
>> Robert Hopkins: 9:00 a.m. Eastern time. Thank
you for joining us for our June 2024 NVAC meeting. Have a great afternoon.
>> Male Speaker:
Produced by the U.S. Department of Health and Human Services.
